CALAA-01

Description:

CALAA-01 is a combination of RONDELâ„¢ and a patented siRNA targeting the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target. CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA). This siRNA inhibits tumor growth via RNA interference to reduce expression of the M2 subunit of ribonucleotide reductase (R2). The CALAA-01 siRNA is protected from nuclease degradation within a stabilized nanoparticle targeted to tumor cells. As of August 2012, this product was in Phase Ib clinical trials.

Information Verified: 
April, 2013

Californa Locations:

Displaying 1 - 1 of 1